Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.85 EPS

Analysts expect that Biodel Inc. (NASDAQ:ALBO) will post earnings of ($0.85) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Biodel’s earnings, with the lowest EPS estimate coming in at ($1.00) and the highest estimate coming in at ($0.76). The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Biodel will report full-year earnings of ($3.69) per share for the current financial year, with EPS estimates ranging from ($4.09) to ($3.38). For the next fiscal year, analysts expect that the company will post earnings of ($3.43) per share, with EPS estimates ranging from ($4.60) to ($2.65). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Biodel.

Biodel (NASDAQ:ALBO) last issued its earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02).

ALBO has been the topic of several recent analyst reports. Zacks Investment Research upgraded Biodel from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Wedbush initiated coverage on Biodel in a research report on Friday, June 30th. They set an “outperform” rating on the stock. Needham & Company LLC initiated coverage on Biodel in a research report on Tuesday, July 18th. They set a “buy” rating and a $35.00 target price on the stock. Finally, Cowen and Company initiated coverage on Biodel in a research report on Wednesday, August 16th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Biodel presently has a consensus rating of “Buy” and an average price target of $40.33.

Shares of Biodel (NASDAQ:ALBO) traded down 0.95% during mid-day trading on Tuesday, hitting $21.95. The company had a trading volume of 4,485 shares. The firm has a 50-day moving average of $23.53 and a 200-day moving average of $22.43. The company’s market cap is $194.96 million. Biodel has a 12 month low of $12.00 and a 12 month high of $37.69.

WARNING: This report was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2017/09/22/analysts-anticipate-biodel-inc-albo-to-announce-0-85-eps.html.

A hedge fund recently raised its stake in Biodel stock. Renaissance Technologies LLC increased its holdings in shares of Biodel Inc. (NASDAQ:ALBO) by 0.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 149,632 shares of the biopharmaceutical company’s stock after buying an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 as of its most recent filing with the Securities and Exchange Commission. 27.36% of the stock is owned by institutional investors.

About Biodel

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Get a free copy of the Zacks research report on Biodel (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biodel (NASDAQ:ALBO)

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply